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SLFN11 is a putative DNA/RNA helicase we discovered as
causally associated with sensitivity to DNA damaging
agents, such as platinum salts, topoisomerase I and II
inhibitors, and other alkylators in the NCI-60 panel of
cancer cell lines [1]. Later, SLFN11 was identified as an
early interferon response gene, in association with HIV
infection [2]. Here we assessed SLFN11 determinants in a
gene expression meta-set of 5,061 breast cancer patients
annotated with clinical data and multigene signatures
obtained with the package genefu [3]. By correlation analy-
sis, we found 537 transcripts above the 95th percentile of
Pearson’s coefficients with SLFN11, identifying “immune
response”, “lymphocyte activation”, and “T cell activation”
as top Gene Ontology enriched processes [4]. Through
multiple correspondence analysis, we discovered a sub-
group of patients characterized by high SLFN11 levels, ER
negativity, basal phenotype, elevated CD3D, STAT1
signature [5], and young age. Fitting a penalized maximum
likelihood lasso regression model [6], we found a strong
multivariable association of SLN11 with the stroma 1 and
stroma 2 signatures [7,8], associated with basal cancer and
response to chemotherapy in ER- tumors. Finally, using
Cox proportional hazard regression, ER-, high prolifera-
tion, high SLFN11 patients undergoing chemotherapy
treatment showed a significantly longer disease-free
interval than other patient categories included in our
model.
Authors’ details
1Department of Internal Medicine (DiMI), University of Genova, Genova, Italy.
2Breast Cancer Translational Research Laboratory J.C. Heuson, Institut Jules
Bordet, Bruxelles, Belgium.
Published: 14 August 2015
References
1. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A,
Doroshow JH, Pommier Y: Putative DNA/RNA helicase Schlafen-11
(SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad
Sci U S A 2012, 109(37):15030-5.
2. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE,
Landry S, Pan T, Weitzman MD, David M: Codon-usage-based inhibition of
HIV protein synthesis by human schlafen 11. Nature 2012,
491(7422):125-8.
3. Haibe-Kains B, Schroeder M, Bontempi G, Sotiriou C, Quackenbush J:
genefu: Relevant Functions for Gene Expression Analysis, Especially in
Breast Cancer. 2014, R package version 1.16.0.
4. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat
Protoc 2009, 4(1):44-57.
5. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G,
Delorenzi M, Piccart M, Sotiriou C: Biological processes associated with
breast cancer clinical outcome depend on the molecular subtypes. Clin
Cancer Res 2008, 14(16):5158-65.
6. Friedman J, Hastie T, Tibshirani R: Regularization Paths for Generalized
Linear Models via Coordinate Descent. J Stat Softw 2010, 33(1):1-22.
7. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V,
AndrÃ© S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J,
Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A
stroma-related gene signature predicts resistance to neoadjuvant
chemotherapy in breast cancer. Nat Med 2009, 15(1):68-74.
8. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H,
Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene
expression predicts clinical outcome in breast cancer. Nat Med 2008,
14(5):518-27.
doi:10.1186/2051-1426-3-S1-O3
Cite this article as: Zoppoli et al.: Clinico-pathological and
transcriptomic determinants of SLFN11 expression in invasive breast
carcinoma. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 1):O3.
1Department of Internal Medicine (DiMI), University of Genova, Genova, Italy
Full list of author information is available at the end of the article
Zoppoli et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 1):O3
http://www.immunotherapyofcancer.org/content/3/S1/O3
© 2015 Zoppoli et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
